• Disease Areas
    • Diabetes
    • Obesity
    • Cardiovascular Disease (CVD)
    • Chronic Kidney Disease (CKD)
    • Metabolic Dysfunction-Associated Steatohepatitis (MASH)
    • Neurodegenerative Diseases
    • Haemophilia
    • Sickle Cell Disease
    • Primary Hyperoxaluria
    • Growth Hormone Disorders
    • Hormone Replacement Therapy
  • Congresses
  • Scientific Publications
  • IME

Search Science Hub

Register Login
My Account
Welcome to Novo Nordisk Science Hub

Are you a healthcare professional?

  • Congresses
  • European Society for Paediatric Endocrinology, 2024 (ESPE)
  • Somapacitan is effective and well tolerated in Chinese children with GHD: 52-week results from the randomized phase 3 REAL6 trial
European Society for Paediatric Endocrinology, 2024 (ESPE)